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Abstract
Background: Crohn's disease (CD) is a principal form of inflammatory bowel disease, affecting approximately 1 in
every 650 people in the UK. Vitamin D deficiency is common in approximately 57.7% of CD patients; with anaemia
occurring in about 43% of patients. There is growing evidence that supplementing CD patients who are vitamin D
deficient may be effective in reducing the severity of CD symptoms and reducing iron-deficiency anaemia.
Nevertheless, National Institute for Health and Care Excellence guidance regarding the management of CD does
not address vitamin D deficiency in these patients. The aims of the study are (1) to determine the prevalence of
vitamin D deficiency in adults with CD in Birmingham, UK and (2) to assess the feasibility of conducting a multi-site
randomised controlled trial in adult patients with CD and vitamin D deficiency.
Methods: D-CODE consists of two parts—a screening study and an open-label randomised controlled feasibility study.
1. Vitamin D screening
Three hundred patients, 18 years or older with CD will have a dried blood spot test to measure vitamin D levels.
Dietary and sun exposure data will be collected. Eligible patients with low levels of vitamin D will be invited to
participate in the feasibility study.
2. Feasibility study
Fifty participants with CD and vitamin D deficiency will be randomised to receive either a low (400 IU daily for 24 weeks) or
high (3200 IU daily for 12 weeks then vitamin D3 800 IU daily for 12 weeks) dose of vitamin D3 oral supplementation.
Patient-reported outcomes (Inflammatory Bowel Disease Questionnaire, EQ-5D-5L and Crohn’s Disease Activity Index Score)
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will be collected at weeks 0 and 24. Biochemical monitoring will take place at weeks 0, 12 and 24 and will measure 25-
hydroxyvitamin D, corrected calcium, albumin, parathyroid hormone, hepcidin, other vitamin D metabolites, iron studies and
C-reactive protein. Faecal calprotectin will be measured at weeks 0 and 24.
Discussion: A key aspect of D-CODE is the identification of vitamin D deficiency prior to supplementation. It is hoped that
this feasibility study will lead to a definitive trial that will investigate the benefits of treating vitamin D deficiency in patients
with CD.
Trial registration: The trial has been registered with EudraCT number 2018-003910-42, ClinicalTrials.gov identifier
NCT03718182 and ISRCTN number 15717783.




Inflammatory bowel diseases (IBD) are both chronic and
often debilitating [1]. IBD is characterised by a mixture
of abdominal pain, diarrhoea, anaemia, fatigue and nutri-
tional problems. Crohn's disease (CD) is one of the prin-
cipal IBD diseases, affecting approximately 1 in every
650 people in the UK [1]. CD may affect any part of the
gastrointestinal tract, from the mouth to the anus, caus-
ing inflammation and ulceration. Patients with active CD
often report having a poor quality of life as a result [2].
CD diagnosis is made by a gastroenterologist in keeping
with best clinical practice including radiology, endoscopy
and histology where possible [3]. Confirmed diagnosis is
recorded in the patient’s clinical documentation. Vita-
min D deficiency is common in patients with CD [4, 5].
A recent meta-analysis of observational studies found
that the overall prevalence of vitamin D deficiency in
CD was 57.7% [6].
The cause of vitamin D deficiency in patients with CD
is likely to be multifactorial with influencing factors
including:
 Reduced sunlight exposure due to their disease-
restricting activity [7]
 Recommendations from medical teams to avoid sunlight
exposure, or use high protection sunscreen, due to the
increased risk of skin cancer with immunosuppressive
treatments such as thiopurines [8]
 Reduced dietary intake of vitamin D due to disease
symptoms and activity [7]
 Malabsorption of fat-soluble vitamins such as vita-
min D. This may be due to bile salt malabsorption,
particularly associated with CD affecting the ter-
minal ileum [9].
A role for vitamin D in iron homeostasis has been pro-
posed [10] [10]. Vitamin D deficiency has been linked to
anaemia in various clinical settings [11], notably in
patients with chronic kidney disease [12]. The precise
mechanism for this has yet to be fully defined but ap-
pears to be linked to direct regulation of the iron-
regulatory protein hepcidin by the active form of vitamin
D, 1,25(OH)2D [13]. Hepcidin acts by inhibiting cellular
export of iron [14]. In the setting of inflammatory disor-
ders such as Crohn’s disease, hepcidin levels are in-
creased in enterocytes and immune cells, resulting in
decreased circulating levels of iron [15]. Vitamin D ap-
pears to counteract this mechanism by transcriptionally
suppressing hepcidin as part of a mechanism for inhibit-
ing access to iron by intracellular pathogens [13].
The National Osteoporosis Society recommends vita-
min D supplementation at blood levels of 25(OH) D of <
50 nmol/L in people who have conditions associated
with malabsorption such as CD [16]. However, current
National Institute for Health Excellence (NICE) guid-
ance regarding the management of CD does not address
vitamin D deficiency in these patients [17]. In this pa-
tient group, standardised vitamin D supplementation
should be considered with regards to maintaining
healthy bones in those receiving corticosteroids [18].
However, there is growing evidence that supplementing
CD patients who are vitamin D deficient may be effect-
ive in both reducing the severity of CD symptoms, such
as anaemia [13] and pain, and reducing the need for sur-
gical intervention [19–21].
Nevertheless, determining an effective dose of vitamin
D supplementation in patients with malabsorption is dif-
ficult. A recent review suggested that vitamin D doses
ranging from 1800 to 10,000 IU daily may be necessary
in patients with IBD [22].
Currently, there is no UK standard practice in terms of
checking vitamin D levels or standard of care in terms of
dose or route of supplementation for patients with CD.
There is a lack of clear national guidance regarding routine
screening and the management of vitamin D deficiency in
patients with CD. A large, multi-centre randomised con-
trolled trial (RCT) would influence and inform national guid-
ance by
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 Establishing if clinical markers of CD are improved
by supplementation in patients with vitamin D
deficiency
 Confirm if quality of life is affected by vitamin D
supplementation in those deplete
 Establishing whether there is a need for routine
screening for vitamin D deficiency in patients with
CD
 Establishing if there is an effective vitamin D
supplementation dose in patients with CD
To answer these questions with authoritative evi-
dence of clinical and cost-effectiveness, a multi-centre
randomised controlled trial (RCT) is required with a
parallel economic evaluation. However, as per Medical
Research Council guidelines [23] smaller feasibility
studies should be conducted first to test methodology
and establish parameters for a full RCT. This will
help ensure success and appropriate use of resources
in a definitive trial.
Objectives
Screening study
Screening was done to determine the prevalence of vita-
min D deficiency in adults with CD in Birmingham, UK
during autumn and winter measured by 25(OH) D
testing.
Feasibility trial
Trial was done to assess the feasibility of conducting a
national, multi-site RCT in adult patients with CD and
vitamin D deficiency and to determine whether vitamin
D supplementation improves clinical markers, symptoms
of disease and reported disease-related disability via as-
sessments of:
 Patient identification and recruitment in to the
feasibility trial
 Identification and analysis of any failure to recruit or
retain participants
 Acceptability to patients of taking a daily oral
vitamin supplement for 24 weeks
 Acceptability to patients of completing
questionnaires and blood tests to be carried out
during the study
 Trial processes, including biochemical and clinical
measurements of Vitamin D metabolites and
hepcidin blood levels and Crohn’s Disease Activity
Index (CDAI)
 Safety of the study intervention and any adverse
events
Trial design
D-CODE is a two-part study entailing two vitamin D
screening studies and an interventional feasibility study.
The vitamin D screening studies will take place during
autumn and winter to determine the prevalence of vita-
min D deficiency in patients with CD during autumn
and winter.
In the intervention/feasibility stage, D-CODE is an ex-
ploratory study to assess the feasibility of an open-label,
multi-site, superiority randomised controlled trial. Par-
ticipants with vitamin D deficiency (< 50 nmol/L serum
25-hydroxyvitamin D [25(OH)D]) will be randomised to
one of two parallel arms (A or B) with a primary end-
point of improvement in symptoms and health-related
quality of life after 24 weeks of treatment for vitamin D
deficiency in patients with CD. The control group (A)
will receive a low dose of vitamin D3 oral capsule 400
IU daily for 24 weeks. The intervention group (B) will
receive a higher treatment dose regimen of vitamin D3
oral capsule 3200 IU daily for 12 weeks followed by 800
IU daily for 12 weeks. This dose is well within the upper
tolerable limit of 4000 IU daily set by the European Food
Standards Agency [24]. Table 1 depicts the participant
pathway and timeline. The D-CODE protocol was de-
signed in accordance with the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
statement [25]. The trial has been registered with
ClinicalTrials.gov identifier NCT03718182 and ISRCTN
number 15717783.
Methods: participants, interventions and
outcomes
Study setting
The D-CODE study is set in secondary and tertiary care
centres in Birmingham, UK. Birmingham is a multi-
cultural and ethnically diverse city. Centre selection in-
cludes one large tertiary referral centre and one large
and one smaller secondary care centre for patients with
CD. The three participating sites have been chosen to
give an effective cross section of different demographic
and ethnic groups across the city.
Eligibility criteria
Inclusion criteria for screening studies are as follow:
1. Those with a confirmed diagnosis of CD
2. Greater than or equal to 18 years of age
3. Have provided written informed consent
Inclusion criteria for the feasibility trial are as follow:
1. Those with a confirmed diagnosis of CD
2. Identified as having vitamin D deficiency < 50
nmol/L 25(OH)D in the screening study
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3. Greater than or equal to 18 years of age
4. Already receiving treatment for CD as per NICE
Guidance or those in remission and not currently
receiving treatment but who continue to attend
out-patient appointments in hospital
5. Has provided written informed consent






















Vitamin D screening Baseline Eligibility Randomisation Intervention phase Final
follow-up
Informed consent X X
Demographics X
Medical history including current
medication list
X X
Confirmation of eligibility X X
Vitamin D dried blood spot test X
Answer lifestyle and food frequency
questions
X X
Telephone contact to arrange baseline
appointment for feasibility trial
X
Randomisation X
Pregnancy test as applicable X
Blood tests:
Vitamin D (25(OH)D) X X X
Calcium X X X
Parathyroid hormone X X X
Albumin X X X
C-reactive protein X X X
Iron studies X X X
Ferritin X X X
Full blood count X X X
Hepcidin X x X
Vitamin D metabolites X X X
Height X
Weight X X X
Stool sample for faecal calprotectin a x x
PROM 1 IBDQ X X
PROM 2 EQ-5D-5L X X
Clinical Assessment 3 CDAI X X X
Adverse event/reaction assessments X X X
Dispensing of trial medication X X
Review of treatment diary X X
Compliance (pill count) X X
Assessment 4 Closing participant
experience questionnaire - postal
X
aIf a faecal calprotectin sample has been taken by the participants of the clinical team within the previous month, a further sample is not required for the study.
The clinical result can be used.
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Exclusion criteria for the feasibility trial are as follow:
1. Currently taking over the counter vitamin D, fish
oil or multivitamin supplementation and unwilling
to stop this to participate in the feasibility trial
2. Currently receiving vitamin D-containing supple-
mentation prescribed by a healthcare professional
3. Currently receiving bisphosphonates
4. Currently receiving Digitalis or other cardiac
glycosides
5. Currently receiving phenytoin
6. Currently receiving barbiturates (e.g.,
Amylobarbitone, Butobarbitone, Methyl
Phenobarbitone, Pentobarbitone, Quinalbarbitone,)
7. Currently receiving actinomycin
8. Currently receiving imidazole
9. With known hyperparathyroidism
10. With known sarcoidosis
11. With known renal disease or kidney stones
12. With known hypercalcaemia (corrected calcium ≥
2.60 mmol/L)
13. With known underlying liver disease
14. With known hypersensitivity to vitamin D
supplements or any of the trial medication
excipients
15. Who are pregnant, breast feeding, trying to
conceive or women of child-bearing capacity who
decline to have a pregnancy test where applicable
and/or decline to take effective contraceptive mea-
sures during the intervention period
16. Individuals who have participated in a trial testing a
medicinal product within 6 months preceding
screening
Patients taking iron supplementation are not excluded
as iron is a common treatment used within CD
management.
Who will take informed consent?
Informed written consent will be taken from partici-
pants prospectively by the site study team. Only
adults (> 18 years old) who have the capacity to pro-
vide consent to participate will be included. Prospect-
ive consent will be collected separately for each part
of the study and consent re-confirmed at each study
visit. A patient information leaflet is provided for
each discrete part. This is because the majority of
participants who take part in the vitamin D screening
study will not be recruited into the intervention feasi-
bility trial. The study will be conducted according to
the principles of Good Clinical Practice (GCP) and to
the ethical principles that have their origin in the
Declaration of Helsinki.
Additional consent provisions for collection and use of
participant data and biological specimens
Not applicable
Interventions
Explanation for the choice of comparators
 Vitamin D3 is recommended by the National
Osteoporosis Society [16] as being the most effective
form of vitamin D supplementation.
 Cholecalciferol is a licensed product in the given
doses and is commercially available.
Arm A: Cholecalciferol 400 IU daily
The rationale is as follows:
 Although some studies have suggested that a dose of
400 IU is too low to be effective [26], it remains the
standard dose recommended by NICE [27] for
treatment of ‘at risk’ groups.
Arm B: Cholecalciferol 3200 IU daily for 12 weeks followed
by Cholecalciferol 800 IU daily for a further 12 weeks
The rationales are as follow:
 The National Osteoporosis Society recommend a
period of a loading dose followed by a period of
maintenance dose [16].
 The European Food Safety Authority [24] set an
upper tolerable limit of 4000 IU daily in adults. 4000
IU is the dose recommended by the Endocrine
Society to treat vitamin D deficiency in those over 8
years old [28].
 It is feasible that a higher dose regimen of vitamin D
will offer greater clinical benefits in patients with
CD in terms of effectively treating their vitamin D
deficiency.
Treatment period
The total treatment period is 24 weeks for both groups.
This is an adequate amount of time for vitamin D levels
to increase to normal limits [16] and for any changes in
patient-reported outcomes to be recognised.
Intervention description In Arm A, Cholecalciferol 400
IU capsules are to be taken orally once daily for a total
of 24 weeks.
In Arm B, Cholecalciferol 3200 IU capsules are to be taken
orally once daily for 12 weeks followed by Cholecalciferol
800 IU capsules to be taken once daily for 12 weeks.
The capsules have a UK marketing authorisation. They
are being used within the terms of the marketing author-
isation and have not been repackaged for use in the trial.
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Therefore, an Annexe 13 label is not required, and a
normal pharmacy dispensing label will be used in ac-
cordance with Schedule 5 of The Medicines for Human
Use (Marketing Authorisations Etc.) Regulations 1994.
Participants will return unused capsules at the 12 and
24 weeks follow-up appointments.
Criteria for discontinuing or modifying allocated
interventions
Patients may prematurely discontinue treatment for any
of the following reasons:
a. The patient withdraws consent.
b. Unacceptable toxicity which requires the treatment
to be permanently discontinued
c. Inter-current illness preventing further treatment.
d. Any change in the patient’s condition that justifies
the discontinuation of treatment in the clinician’s
opinion.
e. A participant becomes pregnant during the trial.
For the follow-up, as per Table 1, participant timeline
will continue unless the patient explicitly also withdraws
consent for follow-up.
Strategies to improve adherence to interventions
Participants will be asked to return all unused vitamin D
supplements to the dispensing pharmacy. Participants
will also be given a treatment diary to record each day
that they take their vitamin D capsule. The treatment
diary will be reviewed at the follow-up appointments at
weeks 12 and 24 as an indication of compliance. Partici-
pants will also give a pragmatic indication of compliance
by indicating if they think they have taken all, most,
some or none of their capsules.
Relevant concomitant care permitted or prohibited during
the trial
As per the product SmPC, concomitant treatment with
Phenytoin or barbiturates can decrease the effect of vita-
min D because of metabolic activation. Concomitant use
of glucocorticoids can decrease the effect of vitamin D.
Simultaneous treatment with ion exchange resins such
as cholestyramine/colesevelam or laxatives such as paraf-
fin oil may reduce the gastrointestinal absorption of vita-
min D. The cytotoxic agent actinomycin and imidazole
antifungal agents interfere with vitamin D activity by
inhibiting the conversion of 25-hydroxyvitamin D to 1,
25-dihydroxyvitamin D by the kidney enzyme, 25-
hydroxyvitamin D-1-hydroxylase.
The effects of digitalis and other cardiac glycosides
may be accentuated with the oral administration of cal-
cium combined with Vitamin D.
However, some of these medications are common
treatments in patients with CD such as glucocorticoster-
oids and cholestyramine/colesevelam. Therefore, these
will be allowed in the study as usual adjunct therapies in
the management of CD; as some of these medications
may act to decrease effectiveness of vitamin D, and there
is no increased risk of toxicity for these participants.
The following concomitant medications are prohibited
within the study:
 Vitamin D, fish oil or multivitamin supplementation
 Bisphosphonates
 Digitalis or other cardiac glycosides
 Phenytoin





Participant’s medication history will be recorded at
baseline and reviewed by a delegated doctor when con-
firming eligibility prior to randomisation, including any
medications that have been started or stopped within
the 2 weeks prior to randomisation. Medication history
will then be checked again at 12- and 24-week visits. All
medications not listed in the prohibited concomitant
medication list are permitted within both treatment
arms.
Provisions for post-trial care
Where participants have perceived benefit from the vita-
min D supplementation, a letter will be sent to their GP
asking them to review this with the patient and consider
continued use.
Outcomes
In screening studies, 25(OH) vitamin D results are mea-
sured in participants to determine prevalence of vitamin
D deficiency < 50 nmol/L during autumn and winter.





4. Completion rates of efficacy outcomes
5. Adverse events
The feasibility of implementing the following measures
in the definitive trial will be assessed:
Primary outcome: Inflammatory Bowel Disease Ques-
tionnaire (IBDQ)
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Secondary outcomes:
1. EQ-5D-5L
2. Crohn’s Disease Activity Index Score (CDAI)
3. Vitamin D (25(OH)D)








Table 1 shows the participant timeline and schedule of
interventions in accordance with SPIRIT.
Sample size
As this is a feasibility study, a formal sample size calcula-
tion is not appropriate; the study is not powered to de-
tect a clinically important difference in any outcomes
between the two treatment groups. Instead, the aims are
to provide robust estimates of the likely rates of recruit-
ment, consent and follow-up and to gain estimates of
the outcome event rates to accurately inform power cal-
culations for a future definitive trial. Various sample
sizes ranging from 24 to 50 have been recommended for
feasibility studies [29–31]. A sample size of 50, the upper
range, has been selected to allow the aims of the study
to be addressed with more confidence.
Fifty patients will be recruited to the intervention part
of the study. Allowing for 20% loss to follow-up, data
will be available for 40 patients. In order to recruit 50
patients into the feasibility trial, 250 patients will need to
be screened to allow for the following:
 Fifty percent of screened patients having vitamin D
deficiency
 Twenty percent of patients with vitamin D
deficiency not eligible
 Fifty percent of eligible patients not consenting
If we identify 100 eligible patients, we will be able to
estimate a consent rate of 50% to within a confidence
interval of ± 10%. If 50 patients are recruited, we will be
able to estimate a retention rate and completion rate (of
efficacy outcomes) of 80% to within a confidence interval
of ± 11%. If we obtain a complete data on 40 patients,
we will be able to estimate the compliance rate and pro-
portion of patients not experiencing an adverse event
(AE) of 80% to within a confidence interval of ± 12%.
The target sample size is divided between the three
hospital settings to ensure a mix of patients, according
to the size of the hospital and likely patient numbers.
For each of the two larger hospitals, in the screening
study, the target is 100 participants, with 20 participants
for the intervention study. The smaller hospital target is
50 participants in the screening study and 10 partici-
pants in the intervention study.
Recruitment
A local retrospective audit identified that over a 2-month
period (March–April 2015) at the Queen Elizabeth Hos-
pital Birmingham, a site of University Hospitals Birming-
ham NHS Foundation Trust (UHBFT), 323 patients with
CD were booked into Gastroenterology out-patient clinics
[32]. It is therefore reasonable to assume that sufficient
patients will attend Gastroenterology clinics across three
sites of UHBFT over a 3-month period.
Participant identification—screening study
Patients attending for their routine CD follow-up out-
patient appointment will be identified by their Gastro-
enterologist for possible inclusion in the screening study.
The Gastroenterologist seeing the patient will identify if,
in their professional opinion, the patient has a confirmed
diagnosis of CD (informed by clinical history, examin-
ation, imaging, endoscopy and/or biopsy results) and
discuss the screening study with the patient avoiding any
coercion. If the patient is interested in participating, the
Gastroenterologist will direct the patient to the study
team within the Gastroenterology Clinic for consent and
participation.
Participant identification—intervention study
Participants from the screening study with a vitamin D
result < 50 nmol/L and who meet the rest of the eligibil-
ity criteria from their reported medical history, may be
identified for possible inclusion in the feasibility trial
within the recruitment period. The study team will
screen potentially eligible patients and contact them by
telephone to explain the intervention study and invite
them to a baseline appointment if they are interested in
participating.
Assignment of interventions: allocation
Sequence generation
Randomisation lists will be generated using block ran-
domisation with random variable block length, stratified
by site. The lists will be produced by an independent
statistician (who is not otherwise involved in the D-
CODE feasibility trial) at the Liverpool Clinical Trials
Centre (LCTC).
Implementation
Participants will be randomised (in a ratio of 1:1) to low-
dose vitamin D (400 IU) or treatment dose vitamin D
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(3200 IU/800 IU) using a secure (24-h) web-based ran-
domisation programme.
Concealment mechanism
The randomisation programme is controlled centrally by
Liverpool Clinical Trials Centre (LCTC), University of
Liverpool to ensure allocation concealment.
Assignment of interventions: blinding
Who will be blinded
D-CODE is an open-label study; therefore, blinding will
not be implemented.
Procedure for unblinding if needed
D-CODE is an open-label study; therefore, blinding will
not be implemented.
Data collection and management
Plans for assessment and collection of outcomes
Screening study
Data will be collected from participants regarding
modifiable risk factors for vitamin D deficiency including
use of over-the-counter or prescribed vitamin D-
containing supplementation, sun exposure, diet and
smoking. Participants will be asked questions related to
 Usual skin exposure to the sun. This will be assessed
by the participants reported wearing usual clothing
worn during warm/sunny weather
 Use of sun protection factor creams/lotion
 Travel within the previous 3 months to a warm/
sunny country outside of the UK
Participants will be asked food frequency questions con-
cerning weekly consumption of key vitamin D-containing
foods including oily fish, red meat, liver, eggs with the yolk
and other fortified foods. Frequency will be determined as
rarely/never, 1–2, 3–4 or > 5 times per week.
Use of vitamin D-containing supplementation will be a
‘yes or no’ to over-the-counter or prescribed supple-
ments and smoking will be a ‘yes-or-no’ response.
Intervention study
Quality of life and patient experience
Patient-reported outcomes have been included to
measure perceived improvement in symptoms and dis-
ease related quality of life for participants.
The Inflammatory Bowel Disease Questionnaire (IBDQ
)[33], a disease-specific questionnaire for adult patients
with IBD, will be used to measure disease-related quality
of life. In a systematic review of patient-reported out-
comes in IBD, Chen et al. [34] reported that the IBDQ has
good validity, reliability and internal consistency, and ex-
cellent content validity and cross-cultural validity; based
on the COSMIN checklist 4-point scale rating of patient
reported outcomes. The EQ-5D-5L (Euroqol) [35], a gen-
eric health utility measure, will also be used to help iden-
tify unanticipated effects of treatment not captured in a
disease-specific questionnaire. The EQ-5D-5L has been
shown to have good validity, reliability and responsiveness
in an evaluation of 502 patients with IBD (CD n = 270,
UC n = 232) [36]. The two questionnaires (IBDQ and EQ-
5D-5L) will be presented as a single, printed paper-based
booklet at the randomisation appointment and after 24
weeks (end of intervention). The endpoint will be an im-
provement from baseline to 24 weeks in the participants
perceived health-related quality of life.
In addition, The Crohn’s Disease Activity Index
(CDAI) [37] will be calculated at 0, 12 and 24 weeks to
quantify the symptoms of patients with CD. The CDAI
is a widely used research and clinical tool that has been
extensively validated. The web-based CDAI-Calculator
from IBD support as recommended by the European
Crohn’s Colitis Organisation will be used to calculate
the CDAI score from non-identifiable patient data
(https://www.ibdsupport.org.au/cdai-calculator).
A short-closing questionnaire will be posted to partici-
pants prior to their final telephone follow-up with a pre-
paid return envelope at 28 weeks. This will be a two-
point questionnaire to explore participants’ experience
and views towards being involved in research.
Plans to promote participant retention and complete
follow-up
If voluntary withdrawal occurs, the patient should be
asked to allow continuation of scheduled evaluations
and complete an end-of-study evaluation if appropriate.
In the event of an AE, the patient should be asked to
allow appropriate care under medical supervision until
the symptoms of any adverse event resolve or the pa-
tient’s condition becomes stable. Follow-up of these pa-
tients will be continued through the PI at each centre
and, where these are unsuccessful, through the patient’s
GP, unless the participant explicitly also withdraws con-
sent for follow-up.
Where patients are thought to be lost to follow-up, at-
tempts will be made to contact the patient: (a) in writing
via the address provided or (b) follow-up telephone call
via the telephone number provided at recruitment.
Where it is thought that patient's contact details may
have changed, the following sources will be checked for
up-to-date contact details: (a) contact details currently
held by the managing hospital site and (b) contact de-
tails currently held by the patient’s GP.
Data management
The D-CODE paper case report form (CRF) is the pri-
mary data collection instrument for the study.
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Completed CRFs will be sent to the LCTC. Patient ques-
tionnaires and diaries are a source document. These will
be photocopied with a copy retained at site and originals
sent to LCTC. Data will be collected pseudo-
anonymised with only participants’ randomisation num-
ber and date of birth recorded on the data collection
tools.
Confidentiality
Individual participant medical information obtained as a
result of this study is considered confidential, and dis-
closure to third parties is prohibited with the exceptions
noted below.
CRFS will be labelled with the patient’s unique trial
screening and/or randomisation number. Medical infor-
mation may be given to the participant’s medical team
and all appropriate medical personnel responsible for the
participant’s welfare. The LCTC will not be undertaking
activities requiring the transfer of identifiable data.
Plans for collection, laboratory evaluation and storage of
biological specimens for genetic or molecular analysis in
this trial/future use
Screening study
Vitamin D dried blood spot tests will be used for
screening patients for vitamin D deficiency in the
screening study. This blood test is taken using the finger
prick sample collection kit which is CE marked and sup-
plied by City Assays, Sandwell and West Birmingham
NHS Trust (http://www.cityassays.org.uk) and analysed
by the Sandwell and West Birmingham Laboratory; Pa-
tients and their GP will be informed of the vitamin D re-
sult from the screening study by post, whether they
participate in the intervention study or not.
Intervention study
Biological specimens for assessing safety
Blood samples will be taken and biochemical measures
will be used for assessing safety and efficacy during the
trial. Safety measures include serum vitamin D
25(OH)D, corrected calcium and parathyroid hormone
(PTH).
Further biochemical measures will be carried out as
follows to inform study results:
a. Inflammation: CRP will be measured to determine
the presence or absence of inflammation. Faecal
calprotectin will be measured as an indication of
CD activity and active inflammation. In clinical
practice, this is an accepted method for monitoring
inflammation in CD and is less invasive than
endoscopic methods.
b. Iron deficiency anaemia: Full blood count and iron
studies (serum iron, total iron binding capacity, iron
saturations, transferrin and ferritin) will be
performed to determine the presence or absence of
iron deficiency anaemia.
Hepcidin will be measured for exploratory and not
diagnostic purposes. A standard serum separation tube
will be used to collect samples. In the laboratory, sam-
ples will be centrifuged within 1 day and serum stored at
− 80 °C until analysis at Birmingham Heartlands Hos-
pital. This is not a routine assay and will be analysed as
a batch at the end of study to ensure consistency.
Serum vitamin D status is conventionally assessed
through measurement of serum levels of 25(OH)D, the
major circulating form of vitamin D. However, it is now
clear that many other vitamin D metabolites are involved
in biological responses to vitamin D, notably the active,
hormonal, form 1,25-dihydroxyvitamin D (1,25(OH)2D).
Researchers at the University of Birmingham have devel-
oped new methodologies to measure multiple metabo-
lites of vitamin D, alongside 25(OH)D, in single serum
samples [38]. These methods will be used to provide a
more detailed perspective of vitamin D status in patients
with Crohn’s disease and determine if metabolites other
than 25(OH)D are linked to changes in the disease.
Samples will be collected in an EDTA sample tube. In
the laboratory, samples will be centrifuged within 1 day
and serum stored at − 20 °C until analysis at the Insti-
tute of Metabolism and Systems Research, University of
Birmingham. Samples will be analysed in batches to en-
sure consistency.
Statistical methods
Statistical methods for primary and secondary outcomes
Screening data will be presented numerically, along
with reasons why patients are ineligible, unwilling to
provide consent or are consented but not rando-
mised. Baseline data will be presented descriptively
to ensure that the patients that have been recruited
are representative of the target population. As this is
a feasibility study and consequently not powered to
detect a significant difference between groups in the
main outcome measures, no comparative analyses
are planned. The main outcome measures will be
presented using summary statistics, and the propor-
tion of missing values will be assessed. The number
of withdrawals (and reasons) will be presented in
each arm. Adverse events will also be presented split
by treatment arm.
Interim analyses
There will be no formal interim analysis but accumulat-
ing data will be presented at regular intervals (at least
annually) for review by an Independent Data Monitoring
and Safety Committee (IDSMC). These analyses will be
performed at the LCTC. The IDSMC will be asked to
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give advice on whether the accumulated data from the
trial, together with results from other relevant trials, jus-
tifies continuing recruitment of further patients or fur-
ther follow-up. A decision to discontinue recruitment, in
all patients or in selected subgroups will be made only if
the result is likely to convince a broad range of clinicians
including participants in the trial and the general clinical
community.
Methods for additional analyses (e.g., subgroup analyses)
Not applicable
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data
Not applicable
Plans to give access to the full protocol, participant level-
data and statistical code
Not applicable
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee
A Trial Management Group (TMG) will be formed com-
prising the Chief Investigator, other lead investigators
(clinical and nonclinical) and members of the LCTC.
The TMG will be responsible for the day-to-day running
and management of the trial.
The Trial Steering Committee (TSC) will consist of an
independent chairperson, 2 independent experts in the
field of Gastroenterology or Endocrinology and a biostatis-
tician, patient and public representation and up to seven
Principal Investigators. The role of the TSC is to provide
overall supervision for the trial and provide advice
through its independent Chairman. The ultimate decision
for the continuation of the trial lies with the TSC.
Composition of the data monitoring committee, its role and
reporting structure
The Independent Data and Safety Monitoring Commit-
tee (IDSMC) consists of an independent chairperson
plus 2 independent members: one of whom is an expert
in the field of IBD, and one who is an expert in medical
statistics. The IDSMC will be responsible for reviewing
and assessing recruitment, interim monitoring of safety
and effectiveness, trial conduct and external data. The
IDSMC will first convene prior to the start of recruit-
ment and will then define frequency of subsequent
meetings (at least annually). The IDSMC will provide a
recommendation to the Trial Steering Committee con-
cerning the continuation of the study.
Adverse event reporting and harms
Safety reporting of adverse events or reactions will be
actively monitored during the feasibility trial from the
period of randomisation until the 28th-week follow-up
appointment. For the purposes of the D-CODE feasibil-
ity trial the following AEs will be
Included
 An exacerbation of a pre-existing illness (excluding CD)
 An increase in frequency or intensity of a pre-
existing episodic event/condition (excluding CD)
 A condition (even though it may have been present
prior to the start of the trial) detected after trial
medication administration
 Laboratory abnormalities that require clinical
intervention or further investigation (unless they are
associated with an already reported clinical event).
 Abnormalities in physiological testing or physical
examination that require further investigation or
clinical intervention
 Injury or accidents
 Symptomatic overdose of trial medication
 Vitamin D toxicity or hypercalcaemia (both
symptomatic and asymptomatic)
Excluded
 Medical or surgical procedures—the condition
which leads to the procedure is the adverse event
 Pre-existing disease or conditions present before
treatment that do not worsen
 Situations where an untoward medical occurrence
has occurred (e.g., cosmetic elective surgery)
 The disease being treated or associated symptoms/
signs, unless more severe than expected for the
patient’s condition
A suspected unexpected serious adverse reaction
(SUSAR) is an adverse reaction that is classed in nature
as serious and which is not consistent with the informa-
tion about the IMP in question, which in the case of a li-
censed product is set out in the SPC for that product.
A serious adverse event is defined as an adverse event
that
 results in death;
 is life threatening;
 requires hospitalisation or prolongation of existing
hospitalisation;
 results in persistent or significant disability or
incapacity;
 consists of a congenital anomaly or birth defect;
 other important medical events.
Serious adverse events will require expedited reporting.
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Notification of deaths
Death is not an expected outcome for participants in the
study, either from the intervention or from the partici-
pants underlying CD. Therefore, participant death dur-
ing the study will be classed as a SUSAR and will
require expedited reporting.
Frequency and plans for auditing trial conduct
The LCTC performs regular internal auditing of LCTC
studies and LCTC systems and processes. In addition,
the study Sponsor conducts a programme of audit car-
ried out by the Trusts Research and Development Gov-
ernance department.
Plans for communicating important protocol amendments
to relevant parties (e.g., trial participants, ethical
committees)
Regulatory approval will be sought for all amendments
to the protocol and communicated to sites and affected
participants.
Dissemination plans
Results will be disseminated via publication and presen-
tation at clinical and scientific conferences. In addition,
the trial website will be updated in a timely manner to
ensure progress reports, and results are easily accessible
to a wide audience. Results will be disseminated regard-
less of the magnitude or direction of effect.
Key target audiences are nurses and medics working
in gastroenterology areas. These practitioners are key in
influencing changes in everyday practice in terms of
screening for vitamin D deficiency in patients with CD.
Discussion
The aim of this study is to determine if it is feasible to
carry out D-CODE as a full multi-centre RCT. There are
few RCTs investigating the general non-skeletal effects
of vitamin D supplementation [39]. Only about a quarter
of these include participants with an identified vitamin
D deficiency, and in terms of CD, evidence for vitamin
D supplementation is mostly observational with some
RCTs giving conflicting evidence [39, 40]. It is reason-
able to assume that patients who are deficient in vitamin
D will gain the greatest benefit from supplementation. A
key aspect of D-CODE is the identification of vitamin D
deficiency prior to supplementation.
Determining a cutoff point for deficiency is conten-
tious with the Scientific Advisory Committee on Nutri-
tion (SACN) [41] in the UK determining vitamin D
deficiency as levels < 25 nmol/L 25(OH)D in terms of
population risk of bone diseases. However, most profes-
sional bodies recognise that this cutoff is too low and
recommend vitamin D levels of at least 50 nmol/L [16,
28], with some suggestion that 75 nmol/L is beneficial in
those with diseases such as CD [42, 43]. In D-CODE, we
have opted for the more conventional cutoff of 50 nmol/L.
Although vitamin D supplementation is available as a
combined therapy with calcium, a randomised, placebo-
controlled trial found that participant compliance was
better with vitamin D supplementation alone as added
calcium may cause gastrointestinal side effects [44].
The primary outcome measure of the main RCT will be
the Inflammatory Bowel Disease Questionnaire (IBDQ).
Patient-reported outcomes are becoming increasingly im-
portant in research. Where biochemical measures may give
an indication of disease activity and efficacy of treatment,
the interpretation of this into lived benefit for the patient is
essential. Hence, two questionnaires are being used in D-
CODE to collect disease-specific and generic health-related
quality of life data. The measurement of vitamin D metabo-
lites beyond the usual and the measurement of hepcidin in
the study offer opportunities to explore novel aspects of
how vitamin D deficiency and supplementation may impact
on CD activity and the association with iron deficiency an-
aemia in this group of patients.
Blinding is often an important aspect of randomised
clinical trials [45]. Therefore, the unblinded nature of
this study is recognised as a limitation. In the feasibility
stage, no comparative analysis is planned. Estimates of
the outcome event rates will be assessed; therefore, we
do not anticipate that the unblinded nature of the feasi-
bility study will adversely affect results. In a definitive
trial blinding will be desirable to prevent bias.
Ultimately, it is hoped that this feasibility study will
lead to a definitive trial that will investigate the benefits
of treating vitamin D deficiency in patients with CD.
This valuable evidence may then be used to inform na-
tional guidance and ensure parity in clinical practice.
Trial status
We are still in the process of recruiting.
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